Background. Pulmonary involvement is one of the hallmark lesions of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) as well as rapidly progressive glomerulonephritis (RPGN). However, the pulmonary involvement of AAV patients seems to differ between Europe and Japan, as does the ANCA serotype. Methods. This retrospective and prospective multicenter cohort study collected the clinical data of the features and outcomes of 1772 RPGN patients treated from 1989 to 2007 in Japan. Based on this nationwide RPGN survey, we analyzed the cases of 1147 AAV patients. Results. We found that 52.3% of the AAV patients had pulmonary involvements: 15.4% of the AAV patients had alveolar hemorrhage (AH), 26.2% had interstitial lung disease (ILD), 2.8% had bronchial asthma, 2.4% had pulmonary granuloma and 12.8% had a chest X-ray abnormality without AH, ILD or pulmonary granuloma. Patient survival was significantly different among the following six groups: the 5-year survival rate was 41.5% in the patients with AH, 50.2% in those with ILD, 67.9% in those with bronchial asthma, 62.5% in those with pulmonary granuloma, 55.8% in those with chest X-ray abnormality and 73.3% in those without pulmonary involvement.
and 10-30% in MPA, but AH is rare in EGPA [3] . Among AAV patients with AH, the most common clinical diagnosis was MPA (52%), followed by GPA (41%) and EGPA (6%) [4] .
Differences in the incidence and ANCA serotype of AAV patients were observed between studies conducted in Europe and Japan [5] . Although the data regarding the overall occurrence of renal vasculitis were similar in Europe and Japan, PR3-ANCA-associated vasculitis (or GPA) seemed to be much less common in Japan. Moreover, differences between studies from Europe and Japan were observed concerning the pulmonary involvement of AAV. Among patients with AAV, interstitial lung disease (ILD), such as pulmonary fibrosis and interstitial pneumonitis, was found to be rare (2-3%) in Europe [6, 7] , but much more frequent in Japan (29-39%) [8, 9] .
Among the ILD patients who were positive for myeloperoxidase (MPO)-ANCA in Japan, 45% demonstrated glomerulonephritis [10] . In an analysis of sequential cohorts of patients with MPA and renal-limited vasculitis collected from European and Japanese centers, the MPA patients in Japan had a significantly higher age at onset, more frequent MPO-ANCA positivity, lower serum creatinine and more frequent ILD compared with the MPA patients in Europe [11] .
To clarify the patient characteristics and prognosis according to the pulmonary lesions of AAV in Japan, in this study we retrospectively analyzed the cases of 1147 AAV patients with rapidly progressive glomerulonephritis (RPGN) based on the previous Japan RPGN registry obtained via a questionnaire survey [12] .
M AT E R I A L S A N D M E T H O D S

Subjects
We retrospectively collected the records of patients with RPGN treated in Japan from 1989 to 1998 and prospectively collected the clinical records of RPGN patients treated from 1999 to 2007 by sending a questionnaire annually by post to 343 nephrology departments of tertiary hospitals in Japan (the names of all of departments are given in the Supplementary data S1). This study was approved by the Medical Ethics Committee at the Graduate School of Comprehensive Human Sciences, University of Tsukuba, in accordance with the guidelines for epidemiological research issued by the Ministry of Health, Labor and Welfare of Japan.
The definition of RPGN was based on the clinical findings of rapidly progressing renal failure over several weeks to a few months, accompanied by the following nephritic urinary abnormalities: hematuria, proteinuria, and red blood cell cast or granular cast in urine sediment. In total, 171 (49.9%) of the 343 nephrology departments responded, and 1772 patients with RPGN were registered [12] .
Among the 1772 RPGN cases, 1147 ANCA-associated renal vasculitis patients were investigated in the present study. ANCA-associated renal vasculitis was diagnosed by each nephrology department, based on characteristic clinical and histological features of small-vessel vasculitis as defined by the Chapel Hill Consensus Conference 1994 [13] , clinical evidence of RPGN and a positive test for ANCA. Patients with other types of systemic small-vessel vasculitis, such as HenochSchönlein purpura, essential cryoglobulinemic vasculitis, druginduced vasculitis, systemic lupus erythematosus, rheumatoid arthritis and malignancy-associated vasculitis were excluded. The cases of patients with anti-glomerular basement membrane (GBM) antibody disease, which was defined as the presence of serum anti-GBM antibody or a linear binding of IgG as detected by direct immunofluorescence, were also excluded.
Investigated parameters
Baseline characteristics including age, gender, height, weight, blood pressure, clinical symptoms, laboratory findings (blood cell counts, biochemical, serological and urinary features) and renal histological findings at presentation were obtained from the patients' clinical records. 'Pulmonary involvement' indicates AH, bronchial asthma, pulmonary granuloma, ILD or the existence of a chest X-ray abnormality. The initial dose of oral prednisolone, the duration of the initial dose, immunosuppressive treatment and plasma exchange (or plasmapheresis) were also recorded. Follow-up clinical data including survival outcome, dialysis dependence, initial date of dialysis therapy, final followup date and cause of death were recorded.
Statistical analysis
Continuous variables are presented as mean ± SD, and categorical variables are presented as numbers with percentages. We used an analysis of variance (ANOVA) to assess differences among subject groups, and post hoc comparisons were made using the Bonferroni/Dunn test. Differences in categorical variables were checked using the χ 2 test, and post hoc comparisons (Bonferroni correction) were performed to detect differences between the groups. Survival rates were estimated with the Kaplan-Meier method, and differences in estimated survival curves were assessed using the log-rank test. End points for patient survival were death, loss to follow-up and closure of study. We tested the parameters of patient characteristics, symptoms and laboratory data (including histological findings) in a univariate Cox analysis, and then we estimated the hazard ratios (HRs) of patient outcomes in a multivariate Cox regression analysis (using the covariates that were significantly associated with the event in the univariate analysis). The relative risk of death is expressed as a HR with 95% confidence interval. Statistical significance was defined as a P-value of <0.05, but in multiple comparisons, the critical P-value (α) was divided by the number of comparisons being made (when one category among six groups was analyzed, the significance threshold was placed at α = 0.05/15 = 0.033). All statistical analyses were performed using PASW Statistics software, version 18 (IBM Japan, Tokyo) for Windows.
had PR3-ANCA (55 AAV patients had both MPO-and PR3-ANCA).
Among the 1147 AAV subjects, 600 AAV patients had pulmonary involvement, 528 patients had AAV without pulmonary involvement and further information ∼19 AAV patients was not available. Among the AAV subjects with pulmonary involvement, 177 patients had AH, 301 had ILD, 32 had bronchial asthma and 27 had pulmonary granuloma. Among the patients without AH, ILD or pulmonary granuloma, the existence of a chest X-ray abnormality was observed in 147 patients. We found that 508 patients had a single pulmonary involvement, 79 had two involvements and 6 had three involvements. Fifty patients had both AH and ILD, six had both AH and pulmonary granuloma, four had both AH and bronchial asthma, five had both ILD and pulmonary granuloma, seven had both ILD and bronchial asthma and seven had both bronchial asthma and chest X-ray abnormality. Among the six patients with three involvements, two patients had AH, ILD and bronchial asthma; two had AH, pulmonary granuloma and bronchial asthma; one had AH, ILD and pulmonary granuloma and one had ILD, pulmonary granuloma and bronchial asthma.
Among the 1088 MPO-AAV subjects, 494 patients had AAV without pulmonary involvement, 167 patients had AH, 291 had ILD, 31 had bronchial asthma, 20 had pulmonary granuloma and 143 had a chest X-ray abnormality without AH, ILD or pulmonary granuloma. Among the 114 AAV subjects with PR3-ANCA, 58 patients had AAV without pulmonary involvement, 18 patients had AH, 20 had ILD, 2 had bronchial asthma, 9 had pulmonary granuloma and 16 had a chest X-ray abnormality.
Lastly, we divided the AAV patients into six groups: the patients with AH (the AH group), patients with ILD (the ILD group), those with bronchial asthma (the BA group), those with pulmonary granuloma (the PG group), those with chest X-ray abnormalities (the X-ray group) and those without pulmonary involvement (the None group). The data of the AAV patients with two or more pulmonary involvements were included in each pulmonary involvement group.
Clinical features and symptoms
Among the six AAV groups, there were no significant differences in gender, height or weight, but the mean age was significantly lower in the None group compared with the other three groups (versus the BA group, P = 0.0032; versus the ILD group, P < 0.0001; versus the X-ray group, P < 0.0001). The mean age in the AH group was significantly lower than that in the ILD group (P = 0.0001) and the X-ray group (P = 0.0005).
The baseline characteristics and symptoms of the patients in the six groups are given in Table 1 . General symptoms such as fever, weight loss, fatigue and appetite loss were frequently observed in the ILD group. The frequencies of arthritis, episcleritis, ear-nose-throat (ENT) symptoms and nasal granuloma were significantly higher in the PG group than that in the None group. Hemosputum was significantly more common in the AH group compared with the X-ray, ILD and None groups. The percentages of bleeding tendency and purpura in the AH group were also significantly higher than those in the X-ray, ILD and None groups. The frequencies of dyspnea, heart disease and peripheral neuropathy were significantly higher in the BA group compared with the None group. Table 2 provides the baseline laboratory and histological findings of the six patient groups. On laboratory examination, the white blood cell count in the None group was significantly lower than that in the other groups except for the PG group, and the serum C-reactive protein level in the None group was significantly lower than that in the other five groups. Hypereosinophilia was highly observed in the BA group. Severe anemia and more deteriorated renal function (blood urea nitrogen and serum creatinine levels) were observed in the AH group. MPO-ANCA was less detected and PR3-ANCA was highly detected in the PG group, but these findings were not significant. There were no significant differences in the urinary examination findings (i.e. urinary protein, urinary occult blood and cellular casts) among the six groups. There were no significant differences in kidney size or histological findings among the six groups.
Laboratory data
Treatments
Oral corticosteroids were administered to 95.3% of the patients (1076/1129), but immunosuppressants were used in 46.4% (516/1112) and plasmapheresis (including plasma exchange) was performed in 13.5% (151/1116) of these AAV patients with RPGN in Japan. The treatments administered to the patients in the six groups are given in Table 3 . There was no significant difference in the frequency of the use of oral corticosteroids among the six groups, but the initial dose of oral corticosteroid, the frequency of use and the daily dose of methylprednisolone pulse therapy in the AH group were all significantly higher than that in the ILD, X-ray and None groups.
There were no differences in the uses of immunosuppressants, the use of oral or intravenous cyclophosphamide, or the doses or times of intravenous cyclophosphamide among the six groups. However, the percentage of patients who received plasma exchange therapy was significantly higher in the AH group than in the ILD, X-ray and None groups.
Outcomes
The cumulative patient survival rate at 1 year for all of the AAV patients was 73.5%, and that at 5 years was 60.1%. There was no significant difference in prognosis among the patients classified by ANCA status ( Figure 1A ). Patient survival was significantly different among the six groups: the 1-year survival was 56.2% in the AH group, 69.9% in the ILD group, 82.1% in the BA group, 69.6% in the PG group, 70.8% in the X-ray group and 82.1% in the None group, whereas the 5-year survival rates were 41.5, 50.2, 67.9, 62.5, 55.8 and 73.3%, respectively ( Figure 1B ). Patient survival in the MPO-ANCApositive AAV patients was significantly different among the six groups ( Figure 1C ) and similar to that in the total AAV patients, but there was no significant difference in patient survival among the PR3-ANCA-positive AAV patients ( Figure 1D ) because of the small numbers of patients.
In the univariate Cox regression analysis for patient survival in AAV (all results of the univariate Cox regression analysis for patient survival in AAV are given in the Supplementary data S2), we found that age, pulmonary involvement, seven symptoms and 12 laboratory data were predictors of 1-year mortality (Table 4) . However, AH, age, bleeding tendency, peripheral neuropathy and serum creatinine level were predictors of 1-year mortality in the multivariate Cox regression analysis for patient survival in AAV. As predictors of 5-year mortality, AH, age and serum creatinine level remained. Moreover, ILD and platelet count were newly added to these three parameters.
Regarding the causes of death (Table 5) , infectious diseases accounted for 41.0% of the deaths (160/390); pulmonary involvements due to AAV were 13.8% (54/390), and the incidence of both diseases together was 20.0% (78/390). Regarding pulmonary involvements due to AAV, the percentage in the AH group was relatively higher (28.9%) than that of the other five groups. Infectious diseases were relatively common in every group, and infectious diseases (including both infection and vasculitis) were relatively more common in the ILD group (68.6%).
D I S C U S S I O N
One of the frequent pulmonary involvements of AAV is AH [3, 4] , and it is also one of the life-threatening manifestations of AAV [14] [15] [16] [17] . However, the mortality due to AH varies among studies. Although AH alone was not associated with increased mortality [18] , AH increased the relative risk at death by 8.6 times in one study [15] . The 1-year survival rate of AAV patients with AH was 82% [16] , but another group reported that 50% of similar patients were alive at their 1-year follow-up [17] . In the present study, the 1-year survival rate was 56.2% and the HR at death by AH was the highest variable; the HR for 1-year survival was ∼3.7 and that for 5-year survival was 3.0. Although the treatment strength of the initial dose of corticosteroid, the percentage of methylprednisolone pulse therapy usage and the frequency of receiving a plasma exchange treatment in the AAV patients with AH were significantly stronger than those in the other pulmonary involvement groups, poor outcomes were observed in the AAV patients with AH.
It was recently demonstrated that renal failure and older age were associated with higher mortality among AAV patients with AH [19] . In the present study, age and serum creatinine level were predictive variables that increased the relative risk at death, as was AH. Moreover, all of the analyzed patients had RPGN (since this study was based on the RPGN survey); this contributed to the poor outcomes of the patients with AH.
AAV with ILD was first reported in 1990 [20] , and several reports of ILD in AAV patients [6-9, 11, 21-32] and ANCApositive ILD patients [10, [33] [34] [35] [36] [37] [38] were published since then. ILD developed more frequently in AAV patients who were MPO-ANCA positive, in particular in those with a diagnosis of MPA, compared with patients with PR3-ANCA-positive AAV [6] [7] [8] [9] [10] [11] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] , and a higher prevalence of ILD has been reported in Asian countries [8, 9, 11, 31, 32] . In the present study, 26% of the AAV patients had ILD and 97% of the AAV patients with ILD had MPO-ANCA, similar to the abovecited studies reporting that AAV patients with ILD had higher percentages of general symptoms (such as fever, weight loss and fatigue), as in previous reports [30, 32] . Regarding the laboratory data, elevated serum C-reactive protein and erythrocyte sedimentation rate levels and abnormal urinalysis and/or renal function were demonstrated in a previous study [32] , but there were no significant differences in inflammatory parameters in that comparison of ILD patients and patients with other pulmonary involvements. A higher prevalence of ILD in this study was also associated with the recruited subjects who had demonstrated RPGN, because renal involvement was frequently observed in AAV patients with ILD [20, 23-26, 30, 32] .
The prognosis of AAV patients with ILD is still unknown; it was reported that there was no significant difference in mortality among patients with and without ILD [7] . However, several studies contended that AAV patients with ILD have a poor prognosis [6, 26, 29, 30, 32] . In the present study, AH was the most life-threatening variable for 1-or 5-year survival, but ILD also increased the relative risk at death at 5 years by ∼2-fold. Therefore, AH may be associated with the short-term prognosis, and ILD may be associated with the long-term prognosis of AAV.
The causes of ILD in AAV are still unclear. Several potential risk factors for ILD have been demonstrated: cigarette smoking, environmental exposures, microbial agents and microaspiration with gastroesophageal reflux [39] . However, unfortunately, we were not able to identify how these factors affected ILD in AAV, because we did not investigate environmental factors including smoking status. In previous studies of ILD in AAV or ANCA-positive ILD patients from Japan, 26-53% of the patients were nonsmokers [10, 34, 36, 38] , and there may be other causes of ILD than smoking.
In the present study, 17% of the ILD patients (50/301) also presented AH. Ultrastructural and immunohistochemical analyses of AAV have demonstrated an association between the vascular injury and the progression of lung fibrosis [40] , and subclinical AH was observed in patients with AAV or urticarial vasculitis [41] [42] [43] . It has thus been suggested that subclinical AH may play a role in the development of pulmonary fibrosis in AAV. However, MPO-ANCA itself may have a pathogenic role in the pulmonary tissue injury of AAV, as was suggested in a study using an animal model of anti-MPO-associated pulmonary vasculitis [44] . The binding of translocated MPO to the surface of neutrophils and circulating ANCA may cause neutrophil degranulation and the release of reactive oxygen species, resulting in pulmonary injury and consequent fibrosis [44, 45] . This hypothesis was supported by the association between MPO-ANCA and ILD in patients with rheumatoid arthritis [46] , but this theory does not explain the pathogenesis of ANCA-negative pulmonary fibrosis. Although ANCA was negative at the diagnosis of ILD, ANCA-positive conversion occurred in several cases, and some of those cases developed AAV [33, 35, 38] . Therefore, further investigations into the pathogenesis of ILD in AAV are needed.
The AAV patients with a chest X-ray abnormality in the present study also had poor prognoses. This group may be heterogeneous; it might include AH patients who did not have hemosputum and/or were not examined by bronchoscopy, patients with pulmonary granuloma who could not be diagnosed histologically and patients with infectious pneumonia. Considering our finding that the major cause of death was infectious disease, infectious pneumonia may have been a complication at the time of diagnosis for some patients. Possible reasons for the poor prognosis of the AAV patients with chest X-ray abnormalities are an insufficient diagnosis and the complication of infectious pneumonia. To improve the outcome of AAV patients with pulmonary involvement, it is necessary to achieve the correct diagnosis of pulmonary lesions by active examinations such as bronchoscopy. Among the present AAV patients with pulmonary granuloma, symptoms of GPA such as arthritis, episcleritis, ENT symptoms and nasal granuloma were frequently observed, and PR3-ANCA was frequently detected. The numbers of patients with these two diseases in this study were relatively small. The reason for a low GPA may be much less common for PR3-ANCA-associated vasculitis in Japan compared with Europe [5] . In the present study, most of the AAV patients with bronchial asthma had specific symptoms of EGPA such as heart disease, peripheral neuropathy and ENT symptoms, and eosinophilia was frequently observed. It would have been appropriate to analyze AAV patients excluded EGPA because of the different prognoses from MPA or GPA. However, we were unfortunately unable to clearly exclude EGPA in this study, because some data were missing. Concerning EGPA, the incidence was similar between Europe and Japan [47] , but renal involvement was observed in 20% of patients with EGPA [48] , and thus, the number of EGPA patients in the present RPGN survey was small. Considering the findings mentioned above, we suspect that most of the investigated subjects had MPA. However, we were unable to clarify the classification of AAV in this study. The classification of AAV has been dependent on the various treating facilities; moreover, the time at which the present study started was before the classification algorithm was published by the European Medicines Agency [49] , and thus, the classification of AAV may be imperfect. On the other hand, in the present study, 50.6% (267/528) of the AAV patients without pulmonary involvement did not have symptoms of other organ involvement; 23.3% (267/1147) of the AAV patients without pulmonary involvement had renal-limited vasculitis. In comparison with Europe, in which 14-25% of AAV patients with renal involvement had renal-limited vasculitis [50, 51] , the frequency of renal-limited vasculitis in Japan is similar.
In the present study, the data of over 1000 AAV patients from across Japan were collected, but part of this study was retrospective and some data were missing because of the questionnaire aspect of the study. Therefore, the time points of the onset of pulmonary involvement in this patient population were not identified, because the collected data were insufficient for this analysis, and the classification for AAV was not perfect. Moreover, the severity of the pulmonary involvements could not be assessed by specific examinations such as blood gas analysis, respiratory function, high-resolution computed tomography and bronchoscopy. In addition, the treatment strength in the AAV patients with AH was significantly stronger. Investigations of the incidence of pulmonary involvements and the accurate outcomes should be conducted as prospective studies with larger numbers of AAV patients.
A prospective study of AAV in Japan demonstrated that 20 (41.7%) of 48 AAV patients had RPGN or pulmonary-renal syndrome [52] . On the other hand, another Japanese prospective study of 156 newly diagnosed AAV patients in Japan showed that 109 (69.9%) of those patients had renal involvements, and 61 (39.1%) of those patients had ILD [11] . That ILD frequency in that study was similar to that of the present study. Moreover, there was no significant difference in the frequency of renal involvement between the AAV patients with ILD and those without ILD in that prospective study [11] . However, AAV patients without renal involvement were not included in the present study, because the study was a part of a nationwide survey of patients with RPGN. Moreover, we did not include cases of AAV patients without ANCA positivity (such as those with ANCA-negative EGPA) or drug-induced AAV patients (such as those with antithyroid agent-associated vasculitis). It is desirable to investigate all patients with ANCA vasculitis, including patients without renal involvement.
In summary, we found that approximately one-half of the AAV patients with RPGN had pulmonary involvement, and that not only AH but also ILD was frequently observed in these AAV patients in Japan. AH was associated with the prognosis, and ILD was associated with the long-term prognosis of AAV.
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